Aventis/Introgen Adenoviral Gene Therapy In Phase III For Head/Neck Cancer
Executive Summary
A Phase III trial of Aventis and Introgen's p53 adenoviral gene therapy is underway for the treatment of head and neck cancer.
You may also be interested in...
Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen
Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.
Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen
Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.
FDA Planning More Inspections Of Gene Therapy Trials During IND Phase
FDA plans to step up inspections of gene therapy trials while they are in the IND phase, FDA Office of Therapeutics Research & Review Director Jay Siegel, MD, told the Senate Health/Public Health Subcommittee during a Feb. 2 hearing on gene therapy.